Preclinical Neurology Deal Benchmarks

The neurology landscape at the preclinical stage is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Development milestones average $619M, regulatory milestones contribute $277M, and commercial milestones reach $171M. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches.

Royalty rates for preclinical neurology deals range from 4.9% to 9.9% at the base tier, with high-tier escalation to 13.9%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.